Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 13,476,331	$ 23,367,456
Prepaid clinical trial costs	540,601	78,295
Prepaid expenses and other current assets	666,435	254,637
Total current assets	14,683,367	23,700,388
Non-current prepaid clinical trial costs	819,721	0
Total Assets	15,503,088	23,700,388
Liabilities
Short-term debt	458,154	0
Accounts payable	6,283,430	3,849,108
Accrued clinical expenses	6,723,719	11,966,812
Accrued compensation	635,587	958,607
Other accrued liabilities	500,616	400,490
Total current liabilities	14,601,506	17,175,017
Warrant liabilities	89,010	806,655
Total Liabilities	14,690,516	17,981,672
Commitments and Contingencies
Stockholders' Equity
Common stock, par value of $0.0001; 315,000,000 shares authorized; 46,579,199 and 27,918,560 shares issued and outstanding as of December 31, 2024 and 2023, respectively	4,658	2,792
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2024 and 2023	0	0
Additional paid-in capital	165,080,964	140,070,172
Accumulated deficit	(164,273,050)	(134,354,248)
Total stockholders' equity	812,572	5,718,716
Total Liabilities and Stockholders' Equity	$ 15,503,088	$ 23,700,388